False Positive Findings on 18F-MFBG PET/CT Attributable to Benign Neural Differentiation in a Pediatric Patient With Neuroblastoma.

Clin Nucl MedApr 20, 2026 (epub)

Siqi Li, Xiaoya Wang, Bingyan Zhang et al.

✦ AI-curated · Sources linked

Case in brief

A 5-year-old girl with high-risk neuroblastoma underwent an 18F-MFBG PET/CT scan to evaluate indeterminate lesions seen on prior imaging. The scan showed moderate uptake in pelvic lymph nodes and the left third sacral foramen. Surgical resection and histopathological analysis revealed mature ganglion cells within Schwannian stroma, indicating benign neural differentiation rather than neuroblastoma recurrence.

What made this case unusual

The case highlights false-positive findings on 18F-MFBG PET/CT due to benign neural differentiation, which is atypical in the context of neuroblastoma imaging.

Diagnostic / clinical pearl

Clinicians should be aware that 18F-MFBG PET/CT may yield false-positive results in pediatric neuroblastoma cases due to benign neural maturation.

Why it matters

Understanding the potential for false positives in imaging can prevent misinterpretation and unnecessary interventions in pediatric patients with neuroblastoma.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.